Bausch Health Companies Inc. (BHC) stock
BHCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3077% below fair value
$8.42+0.07 (+0.84%)
Close on Nov 16, 2026Market cap $3.15BP/E –Yield –
Bausch Health Companies r&d expenses
Research and development expenses are spending on new products and technology.
Bausch Health Companies's R&D Expenses for the twelve months ending Sep 30, 2026 was $638.00M, up 1.1% year over year. For fiscal 2025 it was $629.00M, up 2.1% from the year before. Over ten years it grew 6.5% a year on average. The highest annual figure on record is $629.00M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $629.00M | +2.1% |
| FY2024 | Dec 31, 2024 | $616.00M | +2.0% |
| FY2023 | Dec 31, 2023 | $604.00M | +14.2% |
| FY2022 | Dec 31, 2022 | $529.00M | +13.8% |
| FY2021 | Dec 31, 2021 | $465.00M | +2.9% |
| FY2020 | Dec 31, 2020 | $452.00M | -4.0% |
| FY2019 | Dec 31, 2019 | $471.00M | +14.0% |
| FY2018 | Dec 31, 2018 | $413.00M | +14.4% |
| FY2017 | Dec 31, 2017 | $361.00M | -14.3% |
| FY2016 | Dec 31, 2016 | $421.00M | +26.0% |
| FY2015 | Dec 31, 2015 | $334.00M | +35.8% |
| FY2014 | Dec 31, 2014 | $246.00M | +56.9% |
| FY2013 | Dec 31, 2013 | $156.80M | +98.2% |
| FY2012 | Dec 31, 2012 | $79.10M | +20.4% |
| FY2011 | Dec 31, 2011 | $65.69M | -3.8% |
| FY2010 | Dec 31, 2010 | $68.31M | +43.6% |
| FY2009 | Dec 31, 2009 | $47.58M | -31.8% |
| FY2008 | Dec 31, 2008 | $69.81M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $141.00M | -15.1% |
| Q2 FY2026 | Jun 30, 2026 | $173.00M | +8.8% |
| Q1 FY2026 | Mar 31, 2026 | $163.00M | +14.0% |
| Q4 FY2025 | Dec 31, 2025 | $161.00M | -1.2% |
| Q3 FY2025 | Sep 30, 2025 | $166.00M | +13.7% |
| Q2 FY2025 | Jun 30, 2025 | $159.00M | +1.9% |
| Q1 FY2025 | Mar 31, 2025 | $143.00M | -5.3% |
| Q4 FY2024 | Dec 31, 2024 | $163.00M | +7.2% |
| Q3 FY2024 | Sep 30, 2024 | $146.00M | -4.6% |
| Q2 FY2024 | Jun 30, 2024 | $156.00M | 0.0% |
| Q1 FY2024 | Mar 31, 2024 | $151.00M | +5.6% |
| Q4 FY2023 | Dec 31, 2023 | $152.00M | +7.0% |
| Q3 FY2023 | Sep 30, 2023 | $153.00M | +15.0% |
| Q2 FY2023 | Jun 30, 2023 | $156.00M | +22.8% |
| Q1 FY2023 | Mar 31, 2023 | $143.00M | +12.6% |
| Q4 FY2022 | Dec 31, 2022 | $142.00M | +21.4% |
| Q3 FY2022 | Sep 30, 2022 | $133.00M | +9.9% |
| Q2 FY2022 | Jun 30, 2022 | $127.00M | +10.4% |
| Q1 FY2022 | Mar 31, 2022 | $127.00M | +13.4% |
| Q4 FY2021 | Dec 31, 2021 | $117.00M | -1.7% |
| Q3 FY2021 | Sep 30, 2021 | $121.00M | +17.5% |
| Q2 FY2021 | Jun 30, 2021 | $115.00M | +6.5% |
| Q1 FY2021 | Mar 31, 2021 | $112.00M | -8.2% |
| Q4 FY2020 | Dec 31, 2020 | $119.00M | +4.4% |
| Q3 FY2020 | Sep 30, 2020 | $103.00M | -16.3% |
| Q2 FY2020 | Jun 30, 2020 | $108.00M | -7.7% |
| Q1 FY2020 | Mar 31, 2020 | $122.00M | +4.3% |
| Q4 FY2019 | Dec 31, 2019 | $114.00M | -5.0% |
| Q3 FY2019 | Sep 30, 2019 | $123.00M | +15.0% |
| Q2 FY2019 | Jun 30, 2019 | $117.00M | +24.5% |
| Q1 FY2019 | Mar 31, 2019 | $117.00M | +27.2% |
| Q4 FY2018 | Dec 31, 2018 | $120.00M | +33.3% |
| Q3 FY2018 | Sep 30, 2018 | $107.00M | +32.1% |
| Q2 FY2018 | Jun 30, 2018 | $94.00M | 0.0% |
| Q1 FY2018 | Mar 31, 2018 | $92.00M | -4.2% |
| Q4 FY2017 | Dec 31, 2017 | $90.00M | -3.2% |
| Q3 FY2017 | Sep 30, 2017 | $81.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $94.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $96.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $93.00M | – |
See a number that looks wrong?